Searchable abstracts of presentations at key conferences in endocrinology

ea0056gp29 | Adrenal clinical | ECE2018

Salivary cortisol and cortisone in Cushing diagnosis – reference ranges and clinical cut off limits

Backlund Nils , Brattsand Goran , Israelsson Marlen , Ragnarsson Oskar , Burman Pia , Engstrom Britt Eden , Hoybye Charlotte , Berinder Katarina , Wahlberg Jeanette , Dahlqvist Per

Introduction: Cushing’s syndrome is rare, but assessment of patients with clinical suspicion of Cushing’s and/or adrenal incidentaloma is frequently required. Thus, there is a need for biochemical screening methods that with high sensitivity and specificity identifies or rule out hypercortisolism. Analysis of late night salivary cortisol allows an easy sampling procedure performed at home and is independent of variations in plasma CBG levels. Analysis by liquid chrom...

ea0056p14 | Adrenal cortex (to include Cushing's) | ECE2018

Preoperative treatment with metyrapone in patient with Cushing’s syndrome due to adrenal adenoma: a pilot prospective study

Puglisi Soraya , Perotti Paola , Barbot Mattia , Cosio Paolo , Scaroni Carla , Stigliano Antonio , Lardo Pina , Morelli Valentina , Polledri Elisa , Chiodini Iacopo , Reimondo Giuseppe , Pia Anna , Terzolo Massimo

Background and objectives: Metyrapone has been approved for the treatment of patients with Cushing’s syndrome from all causes, but only few retrospective clinical studies are available. The aim of our study was the prospective assessment of metyrapone as pre-operative treatment.Methods: Before adrenalectomy, 7 patients with ACTH-independent Cushing’s syndrome due to adrenal adenoma were prospectively treated with metyrapone for 3 months, with e...

ea0056p114 | Endocrine tumours and neoplasia | ECE2018

Are there any clinical predictor for malignancy in malignant pheochromocytoma?

Pia Marengo Agustina , Garcia-Sancho Paula , Guerrero Perez Fernando , Peiro Inmaculada , Santacruz Elisa , Ortiz Flores Andres , Jose Diez Juan , Iglesias Pedro , Villabona Carles

Introduction: Malignant pheochromocytoma (MPheo) is diagnosed by the presence of invasion of adjacent structures or distant metastasis. Predictive factors of malignancy for pheochromocytoma (Pheo) are not well known.Material and methods: We retrospectively analyzed clinical, biochemical, radiological characteristics as predictors for malignancy in patients with Pheo in two Spanish tertiary hospitals during the past 35 years. We also evaluated time of rec...

ea0073aep29 | Adrenal and Cardiovascular Endocrinology | ECE2021

Incidental detection of adrenal hyperplasia and mortality in patients with suspected SARS-CoV-2 Infection

Reimondo Giuseppe , Solitro Federica , Puglisi Soraya , Casale Davide , Tiranti Giorgia Maria , Perini Anna , Cultrera Alessandra , Caramello Valeria , Boccuzzi Adriana , Pia Anna , Terzolo Massimo , Veltri Andrea

Many patients affected by SARS-CoV-2 disease (COVID) have associated comorbidities (arterial hypertension, obesity, diabetes mellitus, thrombophilia) that are also tied to autonomous cortisol secretion. However, the prevalence of diseases of the adrenal glands in COVID patients is presently unknown. Since the visualization of the adrenal glands is almost always available in chest CT performed in patients with suspected or confirmed SARS-CoV-2 infection, the evaluation of adren...

ea0073aep560 | Pituitary and Neuroendocrinology | ECE2021

Treatment patterns, healthcare utilization and related costs of acromegaly in a real-world setting in finland

Ilona Iso-Mustajärvi , Tuurinkoski Anna , Juha Mehtälä , Ylisaukko-oja Tero , Merja Väkeväinen , Pia Jaatinen , Camilla Schalin-Jantti

IntroductionAcromegaly is a chronic disease associated with multiple comorbidities and increased incidence of cancer and mortality. The diagnosis often takes several years after the onset of symptoms. The costs of acromegaly in Finland are not known. This study aimed to characterize the treatment patterns, healthcare resource utilization, and direct costs of acromegaly in Finland.MethodsAll adult (≥18 y...

ea0099oc1.3 | Oral Communications 1: Reproductive and Developmental Endocrinology | ECE2024

Pregnancy loss in women with endocrine disorders – a nationwide registry-based cohort study of 366,548 Danish women

Egerup Pia , Bliddal Sofie , Westergaard David , Glintborg Dorte , Bonnema Steen J. , Feldt-Rasmussen Ulla , Nyegaard Mette , Mortensen Laust Hvas , Svarre Nielsen Henriette

Background: Pregnancy loss affects approximately 25% of pregnancies, of which 40% have no detectable chromosome abnormalities and are suspected to be caused by maternal comorbidity. Pregnancy loss has been associated with specific endocrine disorders, e.g. autoimmune thyroid disease (AITD), polycystic ovarian syndrome (PCOS) or diabetes mellitus (DM). Because of the well-described overlap between these endocrine disorders, we hypothesized that pregnancy loss is associated with...

ea0099rc7.6 | Rapid Communications 7: Endocrine-related Cancer | ECE2024

The expression and prognostic value of somatostatin and glucagon-like peptide 1 receptors in insulinoma

Peltola Elina , Vesterinen Tiina , Leijon Helena , Hannula Paivi , Huhtala Heini , Makinen Markus , Nieminen Lasse , Pirinen Elina , Ronty Mikko , Soderstrom Mirva , Arola Johanna , Jaatinen Pia

Insulinomas are rare insulin-producing pancreatic neuroendocrine tumours. Most insulinomas are non-metastatic and can be cured by surgery, but in 10% of the patients insulinomas metastasize, which is associated with a significantly impaired overall survival. As the metastatic potential of an insulinoma cannot be reliably predicted with the current biomarkers, we aimed to evaluate the expression of somatostatin receptors (SSTRs) and glucagon-like peptide-1 receptors (GLP-1Rs) i...

ea0090p381 | Endocrine-related Cancer | ECE2023

Gender related differences in patients with carcinoid syndrome: new insights from a multicenter retrospective study

Grazia Tarsitano Maria , Altieri Barbara , Grossrubatscher Erika , Minotta Roberto , Zamponi Virginia , Albertelli Manuela , Appetecchia Marialuisa , Pia Brizzi Maria , Vittoria Davi Maria , Fanciulli Giuseppe , Giannetta Elisa , Guarnotta Valentina , La Salvia Anna , Lania Andrea , Lavezzi Elisabetta , Malandrino Pasqualino , Mazzilli Rossella , Modica Roberta , Pia Anna , Prinzi Natalie , Pusceddu Sara , Razzore Paula , Zanata Isabella , Chiara Zatelli Maria , Isidori Andrea , Maria Colao Anna , Faggiano Antongiulio , Maddalena Ruggeri Rosaria

The incidence of Neuroendocrine Neoplasm (NEN) and related carcinoid syndrome (CS) increased markedly in recent decades, and women appear to be more at risk than men. As per other tumors, gender may be relevant in influencing the clinical and prognostic characteristics. Unfortunately, there are no studies designed to answer this question in the literature. The present multicentric study was designed to evaluated gender differences, if any, in clinical presentation and outcomes...

ea0081oc2.6 | Oral Communications 2: Adrenal and Cardiovascular Endocrinology 1 | ECE2022

Activity of abiraterone acetate in the management of cushing syndrome associated to advanced adrenocortical carcinoma: results of the ABACUS trial

Puglisi Soraya , Cosentini Deborah , Grisanti Salvatore , Basile Vittoria , Lagana Marta , Ferarri VittorioDomenico , Abate Andrea , Calabrese Anna , Rossini Elisa , Perotti Paola , Saba Laura , Pia Anna , Sigala Sandra , Berruti Alfredo , Terzolo Massimo

Background: More than 50% of adrenocortical carcinomas (ACC) in adults are associated with cortisol excess that makes tumor management challenging and has a negative impact on patient outcome. Abiraterone acetate (AA) is an irreversible inhibitor of the 17α-hydroxylase/C17, 20-lyase (CYP17 enzyme) that is used in patients with prostate cancer, in whom it leads to suppression of cortisol and androgens. The aim of this study was to assess the activity of AA to control corti...

ea0081p10 | Adrenal and Cardiovascular Endocrinology | ECE2022

Comparison of assays for salivary cortisol and cortisone in the diagnosis of Cushing’s syndrome

Backlund Nils , Brattsand Goran , Lundstedt Staffan , Aardal Elisabeth , Bartuseviciene Inga , Katarina Berinder , Burman Pia , Eden Engstrom Britt , Hoybye Charlotte , Isaksson Anders , Ragnarsson Oskar , Ruetschi Ulrika , Wahlberg Jeanette , Olsson Tommy , Dahlqvist Per

Background & Objective: Late night salivary cortisol (LNSC) and 1 mg overnight dexamethasone suppression test (DST) are two of the three recommended screening tests for Cushing’s syndrome (CS). The classical DST uses serum cortisol, but analysis of salivary cortisol and cortisone has shown high diagnostic accuracy at DST (1). Salivary cortisol can be analysed with immunoassays, which suffer from variable degree of cross reactivity with other steroids, or with LC-MS/MS...